Louisiana 2014 Regular Session

Louisiana House Bill HB405

Introduced
3/10/14  
Introduced
3/10/14  
Refer
3/10/14  
Refer
3/10/14  
Report Pass
4/9/14  
Report Pass
4/9/14  
Engrossed
4/21/14  
Engrossed
4/21/14  
Refer
4/22/14  

Caption

Provides relative to prescription of certain campaign finance violations

Companion Bills

No companion bills found.

Previously Filed As

LA HB675

Provides for filing of administrative proceedings before the Ethics Adjudicatory Board for enforcement of certain violations of the Campaign Finance Disclosure Act

LA SB665

Relating To Violations Of Campaign Finance Law.

LA HB906

Makes revisions to the Campaign Finance Disclosure Act (EN INCREASE GF EX See Note)

LA HB596

Provides for revisions to the Campaign Finance Disclosure Act (OR +$97,000 GF EX See Note)

LA SB414

Clarifies the enforcement of certain violations of the Campaign Finance Disclosure Act. (8/1/12)

LA HB693

Provides for revisions to the Campaign Finance Disclosure Act (EN +$97,000 GF EX See Note)

LA HB955

Provides relative to enforcement of certain provisions of the Campaign Finance Disclosure Act

LA HB265

Prohibits the expenditure of campaign funds on certain specified items

LA HB643

Provides for certain campaign finance provisions relative to filing, reporting, and limitations applicable to a deceased candidate under certain circumstances

LA HB1423

Relating To Violations Of Campaign Finance Law.

Similar Bills

HI SB2316

Relating To Health Insurance.

HI HB2194

Relating To Health Insurance.

CA AB2203

Insulin cost-sharing cap.

CA AB587

State government: pharmaceuticals: procurement: collaborative.

AR HB1250

To Amend The Prescription Drug Monitoring Program Advisory Committee; And To Amend The Confidentiality Of And The Providing Of Information By The Prescription Drug Monitoring Program.

IL HB5373

CONT SUB-CHRONIC PAIN TREATMEN

NJ A1845

Limits amount paid by covered persons for purchase of insulin drugs and epinephrine; requires Division of Consumer Affairs to investigate insulin prices.

NJ A1909

Limits amount paid by covered persons for purchase of insulin drugs and epinephrine; requires Division of Consumer Affairs to investigate insulin prices.